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Abstract
Background: This study was designed to examine whether transplantation of mesenchymal stem
cells (MSCs) overexpressing miR-126 enhances angiogenesis in the infarcted myocardium of mice.
Methods: MSCs were harvested from mice using density gradient centrifugation and adher-
ent culture. MSCs were transfected with lentiviral vectors carrying mature miR-126. Mice
models of myocardial infarction were established by ligation of coronary artery. The ligated
animals were randomly divided into three groups (15 in each) and after two weeks, were
intramyocardially injected at the heart infarct zone with miR-126-transfected MSCs (the miR-
-126-MSCs group), MSCs (the MSCs group), or medium (the PBS group). Six weeks later,
histological study and echocardiographic assessment were performed.
Results: Capillary density of the infarcted region was significantly improved in the miR-126-
-MSCs group compared to the MSC group and the PBS group (both p < 0.01). Western blot
showed that ERK1, pERK1, AKT and pAKT gene were dramatically enhanced in the miR-126-
-MSC group compared to the MSC group and the PBS group (both p < 0.05). Echocardiography
showed MiR-126 led to a sustained improvement in cardiac function for at least six weeks at the
injected area, as assessed by left ventricular ejection fraction and fraction of shortening.
Conclusions: Transplantation of MSCs transfected with miR-126 can improve angiogenesis
and cardiac function in the infarcted area of the hearts of mice, which may be due to stimula-
tion of the AKT/ERK-related pathway. (Cardiol J 2011; 18, 6: 675–681)
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Introduction
Ischemic heart disease (IHD) which triggers
dysfunction and the death of cardiomyocytes is the
commonest cause of death throughout the world
despite continued advances in the prevention and
treatment of coronary artery disease [1]. Moreover,
a large number of patients are not qualified for the
conventional revascularization techniques of bal-
loon angioplasty and stenting, or coronary artery
bypass grafting. Stem cells transplantation has been
acclaimed as a promising means for the recovery
of heart function [2–4]. Unfortunately, progress in
stem cell therapy has been hampered by the poor
survival of implanted cells.
MicroRNAs (miRNAs) are an abundant family
of endogenous non-protein-coding small RNAs,
which negatively regulate gene expression at the
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post-transcriptional level in various processes.
Since certain miRNAs are expressed in specific
stem cells and play an important role in regulating
their survival and migratory functions [5], new the-
rapeutic targets for IHD may be identified in these
non-coding RNAs. MiR-126 is an endothelial cell-
-specific miRNA that plays an essential role in
neoangiogenesis following myocardial infarction
(MI) and in the maintenance of vascular integrity.
We put forward the hypothesis that the combina-
tion of MSC transplantation and miR-126 transfer
could be superior to MSC transplantation in the
treatment of myocardial ischemia.
Methods
Cells and plasmid
MSCs from bone marrow aspirates were ob-
tained from C57 mice and grown in MUBMX-90011
medium (Cyagen, Guangzhou, China) supplement-
ed by 1X PBS (PBS-10001-500), 0.25%Trypsin-
-EDTA.
Lentiviral MicroRNAs expression vector was
constructed using the Gateway system (Invitrogen).
Mature miR-126, TRE promoter and eGFP se-
quences were inserted into plasmids to produce
pUp-TRE, pDown-miR126 and pTail-IRES/eGFP;
scramble sequence was set as negative control
(NC). pLV.EX3d.P/puro-TRE > miR126 > IRES/
/eGFP was obtained with incubation of donors and
accepter vectors catalyzed by LR clonase (Gate-
way® LR ClonaseTM Plus Enzyme Mix, Invitrogen).
Plasmid was then sequenced and purified for len-
tivirus envelope.
Lentivirus envelope and bMSCs infection
Envelope helper plasmids: pLV/helper-SL3,
pLV/helper-SL4, pLV/helper-SL5, with pLV.
EX3d.P/puro-TRE-miR126-IRES/eGFP or pLVrtTA/
/neo which contains the imperative elements for
virus packaging, were co-transfected into 293T cells
with lipofectamine 2000, according to the manufa-
cturer’s instructions (Invitrogen) for the generation
of Lenti-miR126-eGFP/puro or Lenti-rtTA/neo re-
spectively. The culture supernatants containing
lentivirus vectors were harvested and ultra-centri-
fuged. The virus titers of each viral preparation
were determined.
To perform lentiviral infections, the mice
MSCs cells were plated at 40–50% confluence and
incubated overnight (16 h). On the day of infections,
the culture medium was replaced by the appropria-
tely titered viral supernatant (1.5 mL/well) and
incubated at 37°C for 10 h; afterwards, the viral
supernatant was replaced by fresh media. Cells
were firstly treated by Lenti-rtTA/neo; 48 h later,
infected cell populations were selected in 0.5 mg/mL
neomycin and refresh medium every two days. Se-
lection was terminated when control cells were
completely dead and antibiotic free medium were
used for propagation. Neomycin resistant cells were
then infected by Lenti-miR126-eGFP/puro and
grown with 2 mg/mL Puromycin. Double resistance
cells were ultimately obtained, and 2 mg/mL doxy-
cycline was added to medium and intrigue expres-
sion of miR-126.
RNA extraction and quantitative
real-time RT-PCR
Approximately 1.0 × 106 MSCs cells (doxycy-
cline treated or not) were seeded into a six-well
culture plate. Cells of each group were harvested
after being cultured for 72 h. Two weeks after cell
transplantation, hearts from the MSC group, the
miR126-MSC group and the PBS group (n = 4/
/group) were excised for ERK1 and pERK1, AKT and
pAKT assay. Hearts thus obtained were snap-fro-
zen in liquid nitrogen. Specimens were homoge-
nized in lysis buffer.
Total RNA was extracted from cells and hearts
with All-in-One miRNA qRT-PCR Detection Kit
(Genecopeia) according to the manufacturer’s in-
structions. Expression of miR-126 was detected by
quantitative real-time RT-PCR (qRT-PCR) using
the All-in-OneTM miRNA qPCR Primer
(Genecopeia); the primer sequence is 5’- CATTAT-
-TACTTTTGGTACGCGAAA-3’. The relative le-
vels of miR-126 transcripts were normalized to the
control U6 mRNA; the primer sequence was
5’-TCGTGAAGCGTTCCATATTTTTAA-3’. Rela-
tive gene expression was quantified using the
GraphPad Prism 4.0 software (GraphPad Software,
San Diego, CA, USA) and expressed as a percent-
age of the control.
Western blot analysis
Different cultures in 35 mm dishes were lysed
in 0.2 mL lysis buffer (0.1% SDS, 1% NP-40, 50 mM
HEPES, pH 7.4, 2 mM EDTA, 100 mM NaCl, 5 mM
sodium orthovanadate, 40 µM p-nitrophenyl phos-
phate, and 1% protease inhibitor mixture set I; Cal-
biochem). Lysates were centrifuged at 12,000 rpm
for 15 min. The supernatant was collected and de-
natured. Proteins were separated in 10% SDS-
-PAGE gel and blotted onto polyvinylidene difluo-
ride membrane. The blot was blocked for 1.5 h at
room temperature in 5% BSA, followed by over-
night incubation at 4oC with AKT, pAKT, ERK1 and
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pERK1 antibodies. Membranes were rinsed and
incubated for 1 h with the corresponding peroxi-
dase-conjugated secondary antibodies. Chemilumi-
nescent detection was performed using the ECL kit
(Pierce).
Myocardial infarction model
All animals received humane care in compli-
ance with the ‘Guide for the Care and Use of Labo-
ratory Animals’ prepared by the Institute of Labo-
ratory Animal Resources, National Research Coun-
cil, and published as the ‘Guide to the Care and Use
of Experimental Animals’ by the Chinese Council
on Animal Care.
Myocardial infarction was induced in 60 experi-
mental C57 mice by ligating the left anterior de-
scending coronary artery (LAD) as previously de-
scribed [6], with some modifications. Briefly, C57
mice were anesthetized with sodium pentobarbital
(50 mg/kg intraperitoneally) and mechanically ven-
tilated. Through a left thoracotomy in the fourth
intercostal space, MI was induced by ligating the
LAD 2 mm from the tip of the left auricle with 6–0
polypropylene (Ethicon, USA). Successful infarction
was determined by observing a rapid occurrence of
akinesia and/or pale discoloration of the left ventri-
cular (LV) muscle [7].
Implantation of MSCs
Sixty C57 mice were used for construction of
the ischemic model. 51 mice were selected from the
56 surviving ligated animals, six of which were ran-
domly re-selected as the model-assessment group
for baseline evaluation of the heart infarcted size.
Two weeks after the ligation, the 45 model AMI
C57 mice were equally randomized to one of three
groups: (1) the MSCs group wherein MSCs in sus-
pension were injected intramuscularly at the left
anterior free wall using an insulin syringe with
a 30-gauge needle; (2) the miR-126-MSCs group,
wherein the animals were injected intramuscular-
ly with miR-126 transfected MSCs suspension; and
(3) the PBS group, where the animals were inject-
ed with PBS. Cell implantation was performed with-
in two weeks after induction of acute MI. PBS or
cell solutions were injected at six injection sites into
anterior and lateral aspects of the viable myocar-
dium bordering the infarction (total 5.0 × 106 cells
in 0.1 mL). After injection, the chest was closed and
the animals were allowed to recover.
Capillary density
Capillary density was determined by immuno-
histochemical staining with anti-VIII factor antibody
42 days after MI as previously described. The tis-
sue sections (5 µm) were stained for factor VIII
(Santa Cruz Biotech, Inc.) to identify capillaries.
Immunohistochemical staining was performed us-
ing the two step immunohistochemical technique
with DAB (Maixin bio, China) as described in the
manufacturer’s specifications. After being restained
with hematine, the samples were coverslipped and
photographed. The cytoplasm of the endothelial
cells was stained red. The capillaries were counted
with a × 200 microscopic objective in ten random-
ly selected fields in two sections per animal and
averaged. Criteria for being counted consisted of
having diameters less than 50 µm and including sin-
gle or tiny vascular endothelial cells.
Cardiac function
Left ventricular function variables were as-
sessed by transthoracic echocardiography, which
was performed six weeks after cell transplantation
using 7.5-MHz phased array transducer (Acuson
Sequoia 256) at time endpoints of each subgroup [8].
Left ventricular internal dimensions (LVID) were mea-
sured as: shortening fraction — FS (%) = [(LVIDD –
– LVIDS)/LVIDD] × 100, ejection fraction —
EF (%) = (EDV – ESV)/EDV × 100%, where D
stands for diastole, S for systole and EDV and ESV
stand for end-diastolic and end-systolic LVID, re-
spectively. All measurements were averaged for
three consecutive cardiac cycles and were carried
out by three experienced technicians who were
unaware of the identity of the experimental groups.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Statistical analysis
Data was expressed as mean ± standard devia-
tion. Statistical analysis was performed using SPSS
software (Release 11.0, SPSS Inc.). The difference
between two groups was analyzed by the Student’s
t-test. A value of p < 0.05 was considered as statis-
tical significance.
Results
MSCs infection and selection
Transfecting MSCs using a traditional chemi-
cal method yielded few results, so we took advan-
tage of lentivirus which declaimed tiny cell toxic and
integrated introduction pattern. Furthermore, an
off-on-off expression system was used in this study.
Lenti-rtTA/neo infected cells were selected with
0.5 g/mL neomycin (2 mg/mL) addition. Non-treat-
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ed MSCs were severely necrosed after 72 h, while
most infected cells survived. Following treatment
with Lenti-miR126-eGFP/puro introduced puromy-
cin resistance into the cells, and controls were killed
by 2 mg/L antibiotic. Next, expressions of miR-126
and green fluorescent protein (GFP) were intrigued,
and doxycyclin was added to the medium. 24 h later,
the test group showed strong GFP expression, which
indicated that the off-on-off expression system func-
tioned.
qPCR test of miR-126
To study the influence of miRNA on MSCs dif-
ferentiation, a ten times higher expression level
is necessary. The TRE promoter induced by doxy-
cycline was proved to be a strong cis-element in
miRNA expression. qPCR test verified that an ap-
proximately 16 times higher expression was ob-
tained (Fig. 1). Primers for 5p of mature sequence
was designed and all results were normalized by
U6 expression in both doxycycline treated and con-
trol cells.
Western blot analysis
miRNAs post-transcriptionally regulate protein
expression. Thus Western blot analysis is crucial
validation before function analysis. We examined
ERK1, pERK1, AKT and pAKT gene, which play key
roles in neoangiogenesis pathways. Results showed
that under higher expression of miR-126, ERK1 and
pERK1, AKT and pAKT were dramatically in-
creased (Fig. 2). The cells were harvested five days
after infection, by when considerable miR-126 had
accumulated.
Six weeks after cell transplantation, there were
low protein levels of ERK1 and pERK1, AKT and
pAKT in the PBS group’s mice hearts. However,
overall ERK1 and pERK1, AKT and pAKT protein
level was significantly higher in the miR-126-MSCs
group’s hearts than in the PBS group’s mice hearts
(p < 0.01; Fig. 3). Moreover, there was also a high-
er level of expression of ERK1 and pERK1, AKT and
pAKT in the miR-126-MSCs group’s hearts com-
pared to the MSCs group’s hearts (p < 0.01; Fig. 3).
Capillary density
Semiquantitative analysis six weeks after
transplantation in vitro demonstrated that the num-
ber of capillary density was significantly increased
in the miR-126-MSCs group and the MSC group
compared to the PBS group (Fig. 4). Moreover, the
number of capillary density was significantly greater
in the miR-126-MSCs group than in the MSC group
(p < 0.05; Fig. 5).
Cardiac function
Echocardiographic assessments of LV function
are shown in Table 1. Results from infarcted C57
mice in the PBS group showed significant reduc-
tion of cardiac function in comparison with the miR-
-126-MSCs and MSCs group. In comparison with the
PBS group, EF and FS in the MSCs group were
improved significantly, by 25% and 24%, respective-
ly (p < 0.01). EF and FS in the miR-126-MSCs
group were 13% and 11% higher than those in the
PBS group (p < 0.05). In comparison with the MSCs
group, EF and FS in the miR-126-MSCs group were
improved significantly, by 12% and 13%, respective-
ly (p < 0.05).
Discussion
Previous studies have suggested a dramatic
improvement in cardiac function after acute MI
through regeneration of the myocardium or neovas-
cularization by transfer of cells derived from bone
marrow (BMC) generated clinical studies [9]. More-
over, growing evidence demonstrates that trans-
plantation of stem cells into the ischemic myocar-
dium with reperfusion is safe and effective.
However, in many studies, as has been shown
in the case of MSC transplantation, the number of
newly differentiated myocytes is too small to ac-
count for all the functional benefits observed with
cell therapy. In addition to the quick loss of cells
within 24 h of transplantation caused by cell leak-
Figure 1. The miR-126 expression level of MSCs. Non-
-DOX indicates cells without doxycycline treatment; DOX
indicates cells with doxycycline treatment. The expres-
sion level was normalized to the GAPDH RNA expres-
sion level and expressed as mean + SD (p < 0.05).
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Figure 4. Factor VIII-related antigen immunohistoche-
mical staining; the positive stain was identified by DAB
which displayed endothelial cells as brown-red. A vary-
ing increase in the number of vessels was shown in the
heart infarcted zone of the miR-126-MSCs (A) and MSCs
(B) groups, while less growth was observed in the PBS
(C) group (200×).
Figure 5. The miR-126-MSCs group had the greatest
capillary density of all the groups, significantly greater
than that of the MSCs and PBS groups (p < 0.05 for all).
Figure 2. Western blot analysis of MSCs infected by
lentivirus; NC — negative control, without doxycycline
treatment; microRNA126 — double infected, with do-
xycycline treatment. Results revealed that under higher
expression of miR-126, ERK and pERK, AKT and pAKT







Figure 3. Western blot analysis of hearts; I — miR-126-
-MSCs group; II — MSCs group; III — PBS group. Ove-
rall ERK1 and pERK1, AKT and pAKT protein level was
significantly higher in the miR-126-MSCs group hearts
than in the PBS groups and the MSCs group mice he-
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age into the extra myocardial space, or being flushed
out in the coronary vein, the major obstacle in the
clinical application of stem cell-based therapy is the
poor viability of the transplanted cells due to harsh
microenvironments like ischemia in the infarcted
myocardium.
The formation of new blood vessels through
neo-angiogenesis is essential for cardiac repair fol-
lowing MI, when collateral vessels form at the site
of the infarct and maintain blood flow to ischemic
tissue [10]. MSCs may differentiate into vascular
endothelium and incorporate into growing capilla-
ries or promote angiogenesis, mitigating the adverse
effects of ventricular remodeling through paracrin-
ing a series of angiogenic cytokines, including vas-
cular endothelial growth factor (VEGF) [11]. Al-
though MSCs are capable of producing a great varie-
ty of cytokines, including VEGF and HGF, their
post-transplantation state may not support high
metabolic activity.
MiR-126 is an endothelial cell-specific miRNA
that plays an essential role in neoangiogenesis fol-
lowing MI and in maintenance of vascular integrity
[12]. MiR-126 represses the expression of SPRED1
and PIK3R2, which negatively regulate VEGF sig-
naling via the ERK and AKT pathways, respective-
ly. VEGF, a highly specific mitogen for vascular
endothelial cells, induces endothelial cell prolife-
ration, promotes cell migration, inhibits apoptosis
and plays a pivotal role in the regulation of vascu-
logenesis [13]. And the expression of the VEGF
gene is restrictedly controlled by a hypoxia-induci-
ble factor [14]. Thus, in the absence of miR-126,
Spred-1/PI3k expression is elevated, resulting in
repression of angiogenic signaling. Conversely,
miR-126 overexpression relieves the repressive
influence of Spred-1/PI3k on the signaling pathways
activated by VEGF and FGF, favoring angiogene-
sis. A subset of miR-126–null mice dies during
embryogenesis from vascular leakage, and those
mutant mice that survive to adulthood are prone to
cardiac rupture and lethality following MI, with
defective neovascularization of the infarct [15].
Knockdown of miR-126 in zebrafish obtained a simi-
lar result.
These findings illustrate that miRNA can regu-
late vascular integrity and angiogenesis, improving
blood flow to ischemic tissue for enhancing viabili-
ty of the transplanted cells.
ERK and Akt are well known kinases that ac-
tivate and promote cell proliferation by stimulating
growth factors. In endothelial cells, VEGF promotes
angiogenesis through the phosphorylation of ERK1
and Akt in rabbit ischemic limb [16] and mouse is-
chemic hind limb [17]. Mangi et al. [18] demonstrat-
ed that transplanted Akt (pro-survival) modified
MSCs could prevent remodeling and restore per-
formance of infarcted hearts. We examined ERK1,
pERK1, AKT and pAKT gene, which play key roles
in neoangiogenesis pathways. Results revealed that
under higher expression of miR-126, ERK1 and
pERK1, AKT and pAKT were dramatically increased
(Fig. 3). Moreover, overall ERK1 and pERK1, AKT
and pAKT protein level was significantly higher in
the miR-126-MSCs group’s hearts than in the PBS
group’s or the MSCs group’s mice hearts (p < 0.01;
Fig 4). Therefore, ERK1 and AKT were adminis-
tered to improve the survival environment of MSCs
and to achieve maximum functional benefits of
MSCs.
In this study, we validated the efficacy and safe-
ty of MSC transplantation after MI in a mouse mod-
el. We characterized the mouse bone marrow-de-
rived MSCs by immunophenotyping and confirmed
that a population of MSCs can be obtained from
a MSC fraction of mouse bone marrow by serial pas-
sage of adherent cells, as described by other inves-
tigators [19, 20]. We demonstrated that MSCs could
be transfected with lentiviral vectors carrying miR-
-126 with high efficiency and without any adverse
effect on cell viability. After transplantation of these
cells, we also found that MSCs overexpressing miR-
-126 survived a long time and effectively expressed
miR-126 for at least six weeks at the injected area.
We showed that the intra-myocardial injection
of MSCs overexpressing miR-126 into ischemic
myocardium significantly enhanced the vessel den-
sity of ischemic tissue after one month in the acute
MI mouse model (Figs. 4A–C). In the in vivo ex-
periment of the present study, the group receiving
Table 1. Cardiac function assessed by echocardiography (X ± S, n = 15).
Cardiac function (42 days after cell transplantation) miR-126-MSCs group MSCs group PBS group
Ejection fraction (%) 87 ± 8*# 74 ± 4& 62 ± 12
Shortening fraction (%) 56 ± 7*# 42 ± 3& 31 ± 8
*p < 0.01, and &p < 0.05 vs the PBS group; #p < 0.05 vs the MSCs group; PBS group, MSCs group and miR-126-MSCs group stand for the groups by
injection of PBS, MSCs and miR-126-MSCs, respectively
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MSCs that over-expressed miR-126 demonstrated
a significantly greater angiogenic and arteriogenic
capacity than the group transplanted with untreat-
ed MSCs.
The major conclusion of this study is that en-
graftment of MiR-126 overexpressing MSCs in the
infarcted myocardium is effective for successful
angiomyogenesis in the infarcted myocardium. In
tandem with the continuous improvement of angio-
genesis, MiR-126 overexpressing MSCs could sus-
tain enhancement of cardiac function in the ischemic
myocardium. In our study, at two weeks after cell
transplantation, the cardiac function in the miR-126-
-MSCs group gradually recovered, whereas the PBS
group demonstrated such effects (Table 1). In
a parallel time frame with the observed enhance-
ment of cardiac function in the miR-126-MSCs
group, the amount of angiogenesis gradually in-
creased. This suggests that angiogenesis played an
important role in the enhancement of cardiac func-
tion. The increased vessel permeability is in favor
of MSCs optimizing the arrangement of extracellu-
lar matrix associating with better support functions
[21, 22], and thus better global heart performance.
Neovascularization in the infarcted myocardium fa-
cilitates the survival and transdifferentiation of im-
planted stem cells. Therefore, it is reasonable to
suggest that miRNA126 is a novel but practical reg-
ulator of stem cell implantation for IHD, and intro-
duces a promising strategy for the treatment of MI.
Conclusions
In summary, our study suggests that MSCs
overexpressing miR-126 transplantation stimulat-
ed vasculogenesis effectively via the AKT/ERK-
-related pathway. For these reasons, this combined
strategy of cell transplantation with MiR-126 thera-
py should prove to be a useful approach in the treat-
ment of IHD.
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